Literature DB >> 25624460

MERTK as negative regulator of human T cell activation.

Raquel Cabezón1, E Antonio Carrera-Silva1, Georgina Flórez-Grau1, Andrea E Errasti1, Elisabeth Calderón-Gómez1, Juan José Lozano1, Carolina España1, Elena Ricart1, Julián Panés1, Carla Vanina Rothlin1, Daniel Benítez-Ribas2.   

Abstract

The aim of this study was to test the hypothesis whether MERTK, which is up-regulated in human DCs treated with immunosuppressive agents, is directly involved in modulating T cell activation. MERTK is a member of the TAM family and contributes to regulating innate immune response to ACs by inhibiting DC activation in animal models. However, whether MERTK interacts directly with T cells has not been addressed. Here, we show that MERTK is highly expressed on dex-induced human tol-DCs and participates in their tolerogenic effect. Neutralization of MERTK in allogenic MLR, as well as autologous DC-T cell cultures, leads to increased T cell proliferation and IFN-γ production. Additionally, we identify a previously unrecognized noncell-autonomous regulatory function of MERTK expressed on DCs. Mer-Fc protein, used to mimic MERTK on DCs, suppresses naïve and antigen-specific memory T cell activation. This mechanism is mediated by the neutralization of the MERTK ligand PROS1. We find that MERTK and PROS1 are expressed in human T cells upon TCR activation and drive an autocrine proproliferative mechanism. Collectively, these results suggest that MERTK on DCs controls T cell activation and expansion through the competition for PROS1 interaction with MERTK in the T cells. In conclusion, this report identified MERTK as a potent suppressor of T cell response. © Society for Leukocyte Biology.

Entities:  

Keywords:  TAM receptors; suppression; tolerogenic dendritic cells

Mesh:

Substances:

Year:  2015        PMID: 25624460      PMCID: PMC4370049          DOI: 10.1189/jlb.3A0714-334R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  38 in total

1.  Tyro-3 family receptors are essential regulators of mammalian spermatogenesis.

Authors:  Q Lu; M Gore; Q Zhang; T Camenisch; S Boast; F Casagranda; C Lai; M K Skinner; R Klein; G K Matsushima; H S Earp; S P Goff; G Lemke
Journal:  Nature       Date:  1999-04-22       Impact factor: 49.962

2.  Efficient clearance of early apoptotic cells by human macrophages requires M2c polarization and MerTK induction.

Authors:  Gaetano Zizzo; Brendan A Hilliard; Marc Monestier; Philip L Cohen
Journal:  J Immunol       Date:  2012-08-31       Impact factor: 5.422

3.  T cell-derived protein S engages TAM receptor signaling in dendritic cells to control the magnitude of the immune response.

Authors:  Eugenio A Carrera Silva; Pamela Y Chan; Leonel Joannas; Andrea E Errasti; Nicola Gagliani; Lidia Bosurgi; Maurice Jabbour; Anthony Perry; Faye Smith-Chakmakova; Daniel Mucida; Hilde Cheroutre; Tal Burstyn-Cohen; Jonathan A Leighton; Greg Lemke; Sourav Ghosh; Carla V Rothlin
Journal:  Immunity       Date:  2013-07-11       Impact factor: 31.745

4.  Apoptotic cells induce Mer tyrosine kinase-dependent blockade of NF-kappaB activation in dendritic cells.

Authors:  Pradip Sen; Mark A Wallet; Zuoan Yi; Yingsu Huang; Michael Henderson; Clayton E Mathews; H Shelton Earp; Glenn Matsushima; Albert S Baldwin; Roland M Tisch
Journal:  Blood       Date:  2006-09-28       Impact factor: 22.113

5.  Phagocytosis and clearance of apoptotic cells is mediated by MER.

Authors:  R S Scott; E J McMahon; S M Pop; E A Reap; R Caricchio; P L Cohen; H S Earp; G K Matsushima
Journal:  Nature       Date:  2001-05-10       Impact factor: 49.962

6.  Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis.

Authors:  A Angelillo-Scherrer; P de Frutos; C Aparicio; E Melis; P Savi; F Lupu; J Arnout; M Dewerchin; M Hoylaerts; J Herbert; D Collen; B Dahlbäck; P Carmeliet
Journal:  Nat Med       Date:  2001-02       Impact factor: 53.440

7.  Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castration-resistant prostate cancer.

Authors:  Punit Saraon; Natasha Musrap; Daniela Cretu; George S Karagiannis; Ihor Batruch; Chris Smith; Andrei P Drabovich; Dominique Trudel; Theodorus van der Kwast; Colm Morrissey; Keith A Jarvi; Eleftherios P Diamandis
Journal:  J Biol Chem       Date:  2012-08-20       Impact factor: 5.157

8.  The mer receptor tyrosine kinase: expression and function suggest a role in innate immunity.

Authors:  Edward M Behrens; Paul Gadue; Shun-you Gong; Stacey Garrett; Paul L Stein; Philip L Cohen
Journal:  Eur J Immunol       Date:  2003-08       Impact factor: 5.532

9.  Lack of protein S in mice causes embryonic lethal coagulopathy and vascular dysgenesis.

Authors:  Tal Burstyn-Cohen; Mary Jo Heeb; Greg Lemke
Journal:  J Clin Invest       Date:  2009-10       Impact factor: 14.808

10.  The receptor tyrosine kinase MerTK regulates dendritic cell production of BAFF.

Authors:  P R Gohlke; J C Williams; B J Vilen; S R Dillon; R Tisch; G K Matsushima
Journal:  Autoimmunity       Date:  2009-03       Impact factor: 2.815

View more
  38 in total

1.  Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response.

Authors:  Eric Ubil; Laura Caskey; Alisha Holtzhausen; Debra Hunter; Charlotte Story; H Shelton Earp
Journal:  J Clin Invest       Date:  2018-04-30       Impact factor: 14.808

2.  Protein S Protects against Podocyte Injury in Diabetic Nephropathy.

Authors:  Fang Zhong; Haibing Chen; Yifan Xie; Evren U Azeloglu; Chengguo Wei; Weijia Zhang; Zhengzhe Li; Peter Y Chuang; Belinda Jim; Hong Li; Firas Elmastour; Jalish M Riyad; Thomas Weber; Hongyu Chen; Yongjun Wang; Aihua Zhang; Weiping Jia; Kyung Lee; John C He
Journal:  J Am Soc Nephrol       Date:  2018-03-06       Impact factor: 10.121

3.  Efferocytosis Modulates Arginase-1 and Tyrosine Kinase Mer Expression in GM-CSF-Differentiated Human Macrophages.

Authors:  L V Sakhno; E Ya Shevela; M A Tikhonova; A A Maksimova; T V Tyrinova; A A Ostanin; E R Chernykh
Journal:  Bull Exp Biol Med       Date:  2021-04-24       Impact factor: 0.804

4.  MerTK as a therapeutic target in glioblastoma.

Authors:  Jing Wu; Lauren N Frady; Ryan E Bash; Stephanie M Cohen; Allison N Schorzman; Yu-Ting Su; David M Irvin; William C Zamboni; Xiaodong Wang; Stephen V Frye; Matthew G Ewend; Erik P Sulman; Mark R Gilbert; H Shelton Earp; C Ryan Miller
Journal:  Neuro Oncol       Date:  2018-01-10       Impact factor: 12.300

5.  Role of Axl in T-Lymphocyte Survival in Salt-Dependent Hypertension.

Authors:  N Batchu; Vyacheslav A Korshunov; Angie Hughson; Kristine M Wadosky; Craig N Morrell; Deborah J Fowell
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-06-30       Impact factor: 8.311

Review 6.  Cellular Abnormalities and Emerging Biomarkers in Alcohol-Associated Liver Disease.

Authors:  Ashwani K Singal; Shannon M Bailey
Journal:  Gene Expr       Date:  2018-07-25

7.  MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.

Authors:  Alisa B Lee-Sherick; Kristen M Jacobsen; Curtis J Henry; Madeline G Huey; Rebecca E Parker; Lauren S Page; Amanda A Hill; Xiaodong Wang; Stephen V Frye; H Shelton Earp; Craig T Jordan; Deborah DeRyckere; Douglas K Graham
Journal:  JCI Insight       Date:  2018-11-02

8.  Sitravatinib potentiates immune checkpoint blockade in refractory cancer models.

Authors:  Wenting Du; Huocong Huang; Noah Sorrelle; Rolf A Brekken
Journal:  JCI Insight       Date:  2018-11-02

9.  Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy.

Authors:  Diana Llopiz; Marta Ruiz; Leyre Silva; David Repáraz; Belén Aparicio; Josune Egea; Juan J Lasarte; Esther Redin; Alfonso Calvo; Matthew Angel; Jay A Berzofsky; David Stroncek; Pablo Sarobe
Journal:  Cancer Lett       Date:  2020-11-21       Impact factor: 8.679

10.  Cbl-b Is Upregulated and Plays a Negative Role in Activated Human NK Cells.

Authors:  Ting Lu; Li Chen; Anthony G Mansour; Melissa J Yu; Noah Brooks; Kun-Yu Teng; Zhenlong Li; Jianying Zhang; Tasha Barr; Jianhua Yu; Michael A Caligiuri
Journal:  J Immunol       Date:  2021-01-08       Impact factor: 5.426

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.